You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethohexital
Accession NumberDB00474  (APRD00058)
TypeSmall Molecule
GroupsApproved
DescriptionAn intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. [PubChem]
Structure
Thumb
Synonyms
(+-)-5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)barbituric acid
5-Allyl-1-methyl-5-(1-methyl-2-pentynyl)-2,4,6(1H,3H,5H)-pyrimidinetrione
5-Allyl-1-methyl-5-(1-methyl-pent-2-ynyl)-pyrimidine-2,4,6-trione
5-Allyl-5-(3-hexyn-2-yl)-1-methylbarbituric acid
alpha-DL-1-Methyl-5-allyl-5-(1'-methylpentyn-2-yl)barbituric acid
Methohexital
Methohexitalum
Methohexitone
Metohexital
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Brevital Sodiuminjection, powder, lyophilized, for solution500 mg/1intramuscular; intravenous; rectalPar Pharmaceutical, Inc.2007-11-01Not applicableUs
Brevital Sodiuminjection, powder, lyophilized, for solution2.5 g/1intramuscular; intravenous; rectalPar Pharmaceutical, Inc.2007-11-01Not applicableUs
Brevital Sodiuminjection, powder, lyophilized, for solution500 mg/1intramuscular; intravenous; rectalA S Medication Solutions Llc2007-11-01Not applicableUs
Brietal Sodium Ampoule 660powder for solution500 mgintravenousEli Lilly Canada Inc1960-12-312000-08-03Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BrevitalNot Available
BrietalNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Methohexital sodium
Thumb
  • InChI Key: KDXZREBVGAGZHS-UHFFFAOYNA-M
  • Monoisotopic Mass: 284.113687095
  • Average Mass: 284.2861
DBSALT000631
Categories
UNIIE5B8ND5IPE
CAS number151-83-7
WeightAverage: 262.3043
Monoisotopic: 262.131742452
Chemical FormulaC14H18N2O3
InChI KeyInChIKey=NZXKDOXHBHYTKP-UHFFFAOYSA-N
InChI
InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)
IUPAC Name
5-(hex-3-yn-2-yl)-1-methyl-5-(prop-2-en-1-yl)-1,3-diazinane-2,4,6-trione
SMILES
CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as barbituric acid derivatives. These are compounds containing a perhydropyrimidine ring substituted at C-2, -4 and -6 by oxo groups.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazines
Sub ClassPyrimidines and pyrimidine derivatives
Direct ParentBarbituric acid derivatives
Alternative Parents
Substituents
  • Barbiturate
  • Ureide
  • 1,3-diazinane
  • Urea
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationMethohexital is indicated for use as an intravenous anaesthetic. It has also been commonly used to induce deep sedation.
PharmacodynamicsMethohexital, a barbiturate, is used for the induction of anesthesia prior to the use of other general anesthetic agents and for induction of anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Little analgesia is conferred by barbiturates; their use in the presence of pain may result in excitation.
Mechanism of actionMethohexital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.
Related Articles
AbsorptionThe absolute bioavailability following rectal administration of methohexital is 17%.
Volume of distributionNot Available
Protein binding73%
Metabolism

Metabolism occurs in the liver through demethylation and oxidation. Side-chain oxidation is the most important biotransformation involved in termination of biologic activity.

Route of eliminationExcretion occurs via the kidneys through glomerular filtration.
Half life5.6 ± 2.7 minutes
ClearanceNot Available
ToxicityThe onset of toxicity following an overdose of intravenously administered methohexital will be within seconds of the infusion. If methohexital is administered rectally or is ingested, the onset of toxicity may be delayed. The manifestations of an ultrashort-acting barbiturate in overdose include central nervous system depression, respiratory depression, hypotension, loss of peripheral vascular resistance, and muscular hyperactivity ranging from twitching to convulsive-like movements. Other findings may include convulsions and allergic reactions. Following massive exposure to any barbiturate, pulmonary edema, circulatory collapse with loss of peripheral vascular tone, and cardiac arrest may occur.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9143
Blood Brain Barrier+0.982
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.6307
P-glycoprotein inhibitor IInhibitor0.5661
P-glycoprotein inhibitor IINon-inhibitor0.9294
Renal organic cation transporterNon-inhibitor0.9297
CYP450 2C9 substrateNon-substrate0.823
CYP450 2D6 substrateNon-substrate0.8823
CYP450 3A4 substrateNon-substrate0.6454
CYP450 1A2 substrateNon-inhibitor0.8001
CYP450 2C9 inhibitorNon-inhibitor0.8179
CYP450 2D6 inhibitorNon-inhibitor0.9099
CYP450 2C19 inhibitorNon-inhibitor0.7836
CYP450 3A4 inhibitorNon-inhibitor0.8501
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.954
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8264
BiodegradationNot ready biodegradable0.9737
Rat acute toxicity2.9098 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.978
hERG inhibition (predictor II)Non-inhibitor0.9697
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Jhp pharmaceuticals llc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionintramuscular; intravenous; rectal2.5 g/1
Injection, powder, lyophilized, for solutionintramuscular; intravenous; rectal500 mg/1
Powder for solutionintravenous500 mg
Prices
Unit descriptionCostUnit
Brevital sodium 2.5 gm vial221.2USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0524 mg/mLALOGPS
logP2.43ALOGPS
logP2.29ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)8.73ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area66.48 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity71.51 m3·mol-1ChemAxon
Polarizability27.4 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (12.5 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0fbc-9520000000-5141cdceea7f6d5013b0View in MoNA
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN01AF01N05CA15
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (184 KB)
MSDSDownload (46.5 KB)
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methohexital is combined with 7-Nitroindazole.
AcebutololMethohexital may increase the hypotensive activities of Acebutolol.
AcenocoumarolThe metabolism of Acenocoumarol can be increased when combined with Methohexital.
AcepromazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Methohexital.
AcetazolamideMethohexital may increase the hypotensive activities of Acetazolamide.
adipiplonThe risk or severity of adverse effects can be increased when Methohexital is combined with adipiplon.
AgomelatineThe risk or severity of adverse effects can be increased when Methohexital is combined with Agomelatine.
AldesleukinMethohexital may increase the hypotensive activities of Aldesleukin.
AlfaxaloneThe risk or severity of adverse effects can be increased when Methohexital is combined with Alfaxalone.
AlfentanilThe risk or severity of adverse effects can be increased when Methohexital is combined with Alfentanil.
AliskirenMethohexital may increase the hypotensive activities of Aliskiren.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methohexital is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methohexital.
AlprenololThe serum concentration of Alprenolol can be decreased when it is combined with Methohexital.
AmilorideMethohexital may increase the hypotensive activities of Amiloride.
AmineptineThe metabolism of Amineptine can be increased when combined with Methohexital.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Methohexital.
AmisulprideThe risk or severity of adverse effects can be increased when Methohexital is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Methohexital is combined with Amitriptyline.
AmlodipineMethohexital may increase the hypotensive activities of Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Methohexital is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Methohexital is combined with Amperozide.
AmrinoneThe metabolism of Amrinone can be increased when combined with Methohexital.
Amyl NitriteMethohexital may increase the hypotensive activities of Amyl Nitrite.
ApraclonidineMethohexital may increase the hypotensive activities of Apraclonidine.
AripiprazoleThe risk or severity of adverse effects can be increased when Methohexital is combined with Aripiprazole.
ArotinololThe serum concentration of Arotinolol can be decreased when it is combined with Methohexital.
ArticaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Articaine.
AsenapineThe risk or severity of adverse effects can be increased when Methohexital is combined with Asenapine.
AtenololMethohexital may increase the hypotensive activities of Atenolol.
AzaperoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Azaperone.
AzelastineMethohexital may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methohexital.
AzelnidipineThe metabolism of Azelnidipine can be increased when combined with Methohexital.
Azilsartan medoxomilMethohexital may increase the hypotensive activities of Azilsartan medoxomil.
AzimilideThe metabolism of Azimilide can be increased when combined with Methohexital.
BaclofenThe risk or severity of adverse effects can be increased when Methohexital is combined with Baclofen.
BarbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Barbital.
BarnidipineThe metabolism of Barnidipine can be increased when combined with Methohexital.
BefunololThe serum concentration of Befunolol can be decreased when it is combined with Methohexital.
BenazeprilMethohexital may increase the hypotensive activities of Benazepril.
BendroflumethiazideMethohexital may increase the orthostatic hypotensive activities of Bendroflumethiazide.
BenidipineThe metabolism of Benidipine can be increased when combined with Methohexital.
BenzocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Benzocaine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methohexital is combined with Benzyl alcohol.
BepridilThe metabolism of Bepridil can be increased when combined with Methohexital.
BetaxololMethohexital may increase the hypotensive activities of Betaxolol.
BevantololThe serum concentration of Bevantolol can be decreased when it is combined with Methohexital.
BisoprololMethohexital may increase the hypotensive activities of Bisoprolol.
BopindololThe serum concentration of Bopindolol can be decreased when it is combined with Methohexital.
BretyliumMethohexital may increase the hypotensive activities of Bretylium.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methohexital is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
BrimonidineMethohexital may increase the hypotensive activities of Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Bromazepam.
BrompheniramineThe risk or severity of adverse effects can be increased when Methohexital is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Brotizolam.
BufuralolThe serum concentration of Bufuralol can be decreased when it is combined with Methohexital.
BumetanideMethohexital may increase the hypotensive activities of Bumetanide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methohexital.
BupranololThe serum concentration of Bupranolol can be decreased when it is combined with Methohexital.
BuprenorphineThe risk or severity of adverse effects can be increased when Methohexital is combined with Buprenorphine.
BuspironeThe risk or severity of adverse effects can be increased when Methohexital is combined with Buspirone.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methohexital.
ButacaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Methohexital is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Methohexital is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Methohexital is combined with Butorphanol.
CanagliflozinMethohexital may increase the hypotensive activities of Canagliflozin.
CandesartanMethohexital may increase the hypotensive activities of Candesartan.
CaptoprilMethohexital may increase the hypotensive activities of Captopril.
CarbamazepineThe risk or severity of adverse effects can be increased when Methohexital is combined with Carbamazepine.
CarbinoxamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Methohexital is combined with Carfentanil.
CarisoprodolThe risk or severity of adverse effects can be increased when Methohexital is combined with Carisoprodol.
CarteololMethohexital may increase the hypotensive activities of Carteolol.
CarvedilolMethohexital may increase the hypotensive activities of Carvedilol.
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Methohexital.
CetirizineThe risk or severity of adverse effects can be increased when Methohexital is combined with Cetirizine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Methohexital is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Methohexital can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlordiazepoxide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Chloroprocaine.
ChlorothiazideMethohexital may increase the orthostatic hypotensive activities of Chlorothiazide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorphenamine.
ChlorpromazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorpromazine.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorprothixene.
ChlorthalidoneMethohexital may increase the orthostatic hypotensive activities of Chlorthalidone.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Chlorzoxazone.
CilazaprilMethohexital may increase the hypotensive activities of Cilazapril.
CilnidipineThe metabolism of Cilnidipine can be increased when combined with Methohexital.
CinchocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Cinchocaine.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Methohexital.
CitalopramThe risk or severity of adverse effects can be increased when Methohexital is combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Methohexital is combined with Clemastine.
ClevidipineMethohexital may increase the hypotensive activities of Clevidipine.
ClidiniumThe risk or severity of adverse effects can be increased when Methohexital is combined with Clidinium.
ClobazamThe risk or severity of adverse effects can be increased when Methohexital is combined with Clobazam.
clomethiazoleThe risk or severity of adverse effects can be increased when Methohexital is combined with clomethiazole.
ClomipramineThe risk or severity of adverse effects can be increased when Methohexital is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Clonazepam.
ClonidineMethohexital may increase the hypotensive activities of Clonidine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Methohexital.
ClorazepateThe risk or severity of adverse effects can be increased when Methohexital is combined with Clorazepate.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methohexital.
CocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methohexital.
CyclizineThe risk or severity of adverse effects can be increased when Methohexital is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Methohexital is combined with Cyclobenzaprine.
CyclosporineThe metabolism of Cyclosporine can be increased when combined with Methohexital.
CyproheptadineThe risk or severity of adverse effects can be increased when Methohexital is combined with Cyproheptadine.
DantroleneThe risk or severity of adverse effects can be increased when Methohexital is combined with Dantrolene.
DapagliflozinMethohexital may increase the hypotensive activities of Dapagliflozin.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methohexital.
DapoxetineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dapoxetine.
DarodipineThe metabolism of Darodipine can be increased when combined with Methohexital.
deramciclaneThe risk or severity of adverse effects can be increased when Methohexital is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Methohexital is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Methohexital is combined with Desipramine.
DesloratadineThe risk or severity of adverse effects can be increased when Methohexital is combined with Desloratadine.
DetomidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Detomidine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dexbrompheniramine.
DexmedetomidineMethohexital may increase the hypotensive activities of Dexmedetomidine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methohexital.
DextromoramideThe risk or severity of adverse effects can be increased when Methohexital is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Methohexital is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dezocine.
DiazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Diazepam.
DiclofenamideMethohexital may increase the hypotensive activities of Diclofenamide.
DicoumarolThe metabolism of Dicoumarol can be increased when combined with Methohexital.
DifenoxinThe risk or severity of adverse effects can be increased when Methohexital is combined with Difenoxin.
DihydrocodeineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydrocodeine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dihydromorphine.
DiltiazemMethohexital may increase the hypotensive activities of Diltiazem.
DimenhydrinateThe risk or severity of adverse effects can be increased when Methohexital is combined with Dimenhydrinate.
DinutuximabMethohexital may increase the hypotensive activities of Dinutuximab.
DiphenhydramineThe risk or severity of adverse effects can be increased when Methohexital is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Methohexital is combined with Diphenoxylate.
DipyridamoleMethohexital may increase the hypotensive activities of Dipyridamole.
DoramectinThe risk or severity of adverse effects can be increased when Methohexital is combined with Doramectin.
DosulepinThe metabolism of Dosulepin can be increased when combined with Methohexital.
DotarizineThe metabolism of Dotarizine can be increased when combined with Methohexital.
DoxazosinMethohexital may increase the hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Methohexital is combined with Doxepin.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Methohexital.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
DoxylamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Methohexital is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methohexital.
DrotebanolThe risk or severity of adverse effects can be increased when Methohexital is combined with Drotebanol.
DyclonineThe risk or severity of adverse effects can be increased when Methohexital is combined with Dyclonine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Methohexital.
EcgonineThe risk or severity of adverse effects can be increased when Methohexital is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Methohexital is combined with ECGONINE METHYL ESTER.
EfavirenzThe risk or severity of adverse effects can be increased when Methohexital is combined with Efavirenz.
EfonidipineThe metabolism of Efonidipine can be increased when combined with Methohexital.
EmpagliflozinMethohexital may increase the hypotensive activities of Empagliflozin.
EnalaprilMethohexital may increase the hypotensive activities of Enalapril.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methohexital.
EntacaponeThe risk or severity of adverse effects can be increased when Methohexital is combined with Entacapone.
EperisoneThe metabolism of Eperisone can be increased when combined with Methohexital.
EplerenoneMethohexital may increase the hypotensive activities of Eplerenone.
EprosartanMethohexital may increase the hypotensive activities of Eprosartan.
EscitalopramThe risk or severity of adverse effects can be increased when Methohexital is combined with Escitalopram.
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Methohexital.
EsmololMethohexital may increase the hypotensive activities of Esmolol.
EstazolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Estazolam.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methohexital.
Etacrynic acidMethohexital may increase the hypotensive activities of Etacrynic acid.
EthanolMethohexital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methohexital.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methohexital.
EthosuximideThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethotoin.
Ethyl biscoumacetateThe metabolism of Ethyl biscoumacetate can be increased when combined with Methohexital.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Methohexital is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Etizolam.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methohexital.
EtoperidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Methohexital is combined with Etorphine.
EzogabineThe risk or severity of adverse effects can be increased when Methohexital is combined with Ezogabine.
FelbamateThe serum concentration of Methohexital can be increased when it is combined with Felbamate.
FelbamateThe risk or severity of adverse effects can be increased when Methohexital is combined with Felbamate.
FelodipineMethohexital may increase the hypotensive activities of Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Fencamfamine.
FendilineThe metabolism of Fendiline can be increased when combined with Methohexital.
FenfluramineThe risk or severity of adverse effects can be increased when Methohexital is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Methohexital is combined with Fentanyl.
FexofenadineThe risk or severity of adverse effects can be increased when Methohexital is combined with Fexofenadine.
FlibanserinThe risk or severity of adverse effects can be increased when Methohexital is combined with Flibanserin.
FludiazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be increased when combined with Methohexital.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methohexital.
FlunitrazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Flunitrazepam.
FluoxetineThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Methohexital is combined with Flupentixol.
FluphenazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluphenazine.
FlurazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Flurazepam.
FluspirileneThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluspirilene.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluticasone Propionate.
FluvoxamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Fluvoxamine.
FosinoprilMethohexital may increase the hypotensive activities of Fosinopril.
FosphenytoinThe risk or severity of adverse effects can be increased when Methohexital is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Methohexital is combined with Fospropofol.
FurosemideMethohexital may increase the hypotensive activities of Furosemide.
GabapentinThe metabolism of Gabapentin can be increased when combined with Methohexital.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methohexital.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methohexital is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Methohexital is combined with Gamma Hydroxybutyric Acid.
GlutethimideThe risk or severity of adverse effects can be increased when Methohexital is combined with Glutethimide.
GriseofulvinThe serum concentration of Griseofulvin can be decreased when it is combined with Methohexital.
GuanfacineMethohexital may increase the hypotensive activities of Guanfacine.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methohexital.
HalazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Halazepam.
HaloperidolThe risk or severity of adverse effects can be increased when Methohexital is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Methohexital is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Methohexital is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Hexobarbital.
HydralazineMethohexital may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideMethohexital may increase the orthostatic hypotensive activities of Hydrochlorothiazide.
HydrocodoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Hydrocodone.
HydroflumethiazideMethohexital may increase the orthostatic hypotensive activities of Hydroflumethiazide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methohexital.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
HydroxyzineThe risk or severity of adverse effects can be increased when Methohexital is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Iloperidone.
ImipramineThe risk or severity of adverse effects can be increased when Methohexital is combined with Imipramine.
IndalpineThe risk or severity of adverse effects can be increased when Methohexital is combined with Indalpine.
IndapamideMethohexital may increase the orthostatic hypotensive activities of Indapamide.
IndenololThe serum concentration of Indenolol can be decreased when it is combined with Methohexital.
IrbesartanMethohexital may increase the hypotensive activities of Irbesartan.
IsofluraneThe risk or severity of adverse effects can be increased when Methohexital is combined with Isoflurane.
Isosorbide DinitrateMethohexital may increase the hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitrateMethohexital may increase the hypotensive activities of Isosorbide Mononitrate.
IsoxsuprineMethohexital may increase the hypotensive activities of Isoxsuprine.
IsradipineMethohexital may increase the hypotensive activities of Isradipine.
KetamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketamine.
KetazolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketazolam.
KetobemidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Ketobemidone.
LabetalolMethohexital may increase the hypotensive activities of Labetalol.
LacidipineThe metabolism of Lacidipine can be increased when combined with Methohexital.
LamotrigineThe metabolism of Lamotrigine can be increased when combined with Methohexital.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methohexital.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Methohexital.
LevetiracetamThe risk or severity of adverse effects can be increased when Methohexital is combined with Levetiracetam.
LevobunololMethohexital may increase the hypotensive activities of Levobunolol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Methohexital is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Methohexital is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Methohexital is combined with Levodopa.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methohexital is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Methohexital is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Methohexital is combined with Levorphanol.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methohexital.
LisinoprilMethohexital may increase the hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Methohexital is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Methohexital is combined with Lofentanil.
LoratadineThe risk or severity of adverse effects can be increased when Methohexital is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methohexital.
LosartanMethohexital may increase the hypotensive activities of Losartan.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methohexital.
Lu AA21004The risk or severity of adverse effects can be increased when Methohexital is combined with Lu AA21004.
LurasidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Lurasidone.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
Magnesium SulfateThe metabolism of Magnesium Sulfate can be increased when combined with Methohexital.
ManidipineThe metabolism of Manidipine can be increased when combined with Methohexital.
MannitolMethohexital may increase the hypotensive activities of Mannitol.
MaprotilineThe risk or severity of adverse effects can be increased when Methohexital is combined with Maprotiline.
MecamylamineMethohexital may increase the hypotensive activities of Mecamylamine.
MeclizineThe risk or severity of adverse effects can be increased when Methohexital is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Medetomidine.
MelatoninThe risk or severity of adverse effects can be increased when Methohexital is combined with Melatonin.
MelperoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Melperone.
MepivacaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Mepivacaine.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methohexital.
MesoridazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Mesoridazine.
MetaxaloneThe risk or severity of adverse effects can be increased when Methohexital is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methohexital.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methohexital is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Methohexital is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Methaqualone.
MethazolamideMethohexital may increase the hypotensive activities of Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Methohexital is combined with Methocarbamol.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Methotrimeprazine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methohexital is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Methohexital is combined with Methsuximide.
MethyclothiazideMethohexital may increase the orthostatic hypotensive activities of Methyclothiazide.
MethyldopaMethohexital may increase the hypotensive activities of Methyldopa.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methylphenobarbital.
MetipranololMethohexital may increase the hypotensive activities of Metipranolol.
MetolazoneMethohexital may increase the orthostatic hypotensive activities of Metolazone.
MetoprololMethohexital may increase the hypotensive activities of Metoprolol.
MetyrosineMethohexital may increase the sedative activities of Metyrosine.
MianserinMianserin may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
MibefradilThe metabolism of Mibefradil can be increased when combined with Methohexital.
MidazolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Midazolam.
MilnacipranThe risk or severity of adverse effects can be increased when Methohexital is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
MinoxidilMethohexital may increase the hypotensive activities of Minoxidil.
MirtazapineMethohexital may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methohexital.
MoexiprilMethohexital may increase the hypotensive activities of Moexipril.
MolindoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Molindone.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methohexital.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methohexital.
NabiloneThe risk or severity of adverse effects can be increased when Methohexital is combined with Nabilone.
NadololMethohexital may increase the hypotensive activities of Nadolol.
NalbuphineThe risk or severity of adverse effects can be increased when Methohexital is combined with Nalbuphine.
NebivololMethohexital may increase the hypotensive activities of Nebivolol.
NesiritideMethohexital may increase the hypotensive activities of Nesiritide.
NicardipineMethohexital may increase the hypotensive activities of Nicardipine.
NifedipineMethohexital may increase the hypotensive activities of Nifedipine.
NiguldipineThe metabolism of Niguldipine can be increased when combined with Methohexital.
NiludipineThe metabolism of Niludipine can be increased when combined with Methohexital.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Methohexital.
NimesulideThe metabolism of Nimesulide can be increased when combined with Methohexital.
NimodipineMethohexital may increase the hypotensive activities of Nimodipine.
NisoldipineMethohexital may increase the hypotensive activities of Nisoldipine.
NitrazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Methohexital.
NitroglycerinMethohexital may increase the hypotensive activities of Nitroglycerin.
NitroprussideMethohexital may increase the hypotensive activities of Nitroprusside.
Nitrous oxideThe risk or severity of adverse effects can be increased when Methohexital is combined with Nitrous oxide.
NormethadoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Methohexital is combined with Nortriptyline.
OlanzapineThe risk or severity of adverse effects can be increased when Methohexital is combined with Olanzapine.
OlmesartanMethohexital may increase the hypotensive activities of Olmesartan.
OlopatadineThe risk or severity of adverse effects can be increased when Methohexital is combined with Olopatadine.
OndansetronThe risk or severity of adverse effects can be increased when Methohexital is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Methohexital is combined with Opium.
OrphenadrineMethohexital may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methohexital.
OsanetantThe risk or severity of adverse effects can be increased when Methohexital is combined with Osanetant.
OxazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxazepam.
OxprenololThe serum concentration of Oxprenolol can be decreased when it is combined with Methohexital.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methohexital.
OxybuprocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxybuprocaine.
OxycodoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Oxymorphone.
PaliperidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Paliperidone.
PapaverineMethohexital may increase the hypotensive activities of Papaverine.
ParaldehydeMethohexital may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Methohexital.
ParoxetineThe risk or severity of adverse effects can be increased when Methohexital is combined with Paroxetine.
PenbutololMethohexital may increase the hypotensive activities of Penbutolol.
PentazocineThe risk or severity of adverse effects can be increased when Methohexital is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methohexital.
PerampanelThe risk or severity of adverse effects can be increased when Methohexital is combined with Perampanel.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Methohexital.
PerindoprilMethohexital may increase the hypotensive activities of Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Methohexital is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Perphenazine.
PethidineMethohexital may increase the central nervous system depressant (CNS depressant) activities of Pethidine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methohexital.
PhenindioneThe metabolism of Phenindione can be increased when combined with Methohexital.
PhenobarbitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Phenobarbital.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methohexital is combined with Phenoxyethanol.
PhenprocoumonThe metabolism of Phenprocoumon can be increased when combined with Methohexital.
PhenytoinThe risk or severity of adverse effects can be increased when Methohexital is combined with Phenytoin.
PimozideThe risk or severity of adverse effects can be increased when Methohexital is combined with Pimozide.
PinaveriumThe metabolism of Pinaverium can be increased when combined with Methohexital.
PindololMethohexital may increase the hypotensive activities of Pindolol.
PipamperoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Pipotiazine.
PizotifenThe risk or severity of adverse effects can be increased when Methohexital is combined with Pizotifen.
PolythiazideMethohexital may increase the orthostatic hypotensive activities of Polythiazide.
PomalidomideThe risk or severity of adverse effects can be increased when Methohexital is combined with Pomalidomide.
PractololThe serum concentration of Practolol can be decreased when it is combined with Methohexital.
PramipexoleMethohexital may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Pramocaine.
PrazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Prazepam.
PrazosinMethohexital may increase the hypotensive activities of Prazosin.
PregabalinThe metabolism of Pregabalin can be increased when combined with Methohexital.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methohexital.
PrenylamineThe metabolism of Prenylamine can be increased when combined with Methohexital.
PrilocaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Prilocaine.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Methohexital.
ProcaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methohexital.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methohexital.
PromethazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Promethazine.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Methohexital.
ProparacaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Methohexital is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Propoxycaine.
PropranololMethohexital may increase the hypotensive activities of Propranolol.
ProtriptylineThe risk or severity of adverse effects can be increased when Methohexital is combined with Protriptyline.
PSD502The risk or severity of adverse effects can be increased when Methohexital is combined with PSD502.
PyridoxineThe metabolism of Methohexital can be increased when combined with Pyridoxine.
QuazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Quazepam.
QuetiapineMethohexital may increase the hypotensive activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methohexital.
QuinaprilMethohexital may increase the hypotensive activities of Quinapril.
QuinethazoneMethohexital may increase the orthostatic hypotensive activities of Quinethazone.
RamelteonThe risk or severity of adverse effects can be increased when Methohexital is combined with Ramelteon.
RamiprilMethohexital may increase the hypotensive activities of Ramipril.
RemifentanilThe risk or severity of adverse effects can be increased when Methohexital is combined with Remifentanil.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methohexital.
ReserpineMethohexital may increase the hypotensive activities of Reserpine.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methohexital.
RiociguatMethohexital may increase the hypotensive activities of Riociguat.
RisedronateThe metabolism of Risedronate can be increased when combined with Methohexital.
RisperidoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Risperidone.
RomifidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Romifidine.
RopiniroleMethohexital may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methohexital.
RotigotineMethohexital may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methohexital.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Methohexital is combined with S-Ethylisothiourea.
ScopolamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methohexital.
SertindoleThe risk or severity of adverse effects can be increased when Methohexital is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Methohexital is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Methohexital is combined with Sevoflurane.
Sodium oxybateThe risk or severity of adverse effects can be increased when Methohexital is combined with Sodium oxybate.
SomatostatinThe risk or severity of adverse effects can be increased when Somatostatin is combined with Methohexital.
SotalolMethohexital may increase the hypotensive activities of Sotalol.
SpironolactoneMethohexital may increase the hypotensive activities of Spironolactone.
StiripentolThe risk or severity of adverse effects can be increased when Methohexital is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Methohexital is combined with Sufentanil.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methohexital.
SuvorexantThe risk or severity of adverse effects can be increased when Methohexital is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Methohexital is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Methohexital is combined with Tasimelteon.
TelmisartanMethohexital may increase the hypotensive activities of Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methohexital.
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Methohexital.
TerazosinMethohexital may increase the hypotensive activities of Terazosin.
TetrabenazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Methohexital is combined with Tetrodotoxin.
ThalidomideMethohexital may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methohexital.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Methohexital.
ThiamylalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Thioridazine.
ThiothixeneThe risk or severity of adverse effects can be increased when Methohexital is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Methohexital is combined with Tiagabine.
TianeptineThe metabolism of Tianeptine can be increased when combined with Methohexital.
TiletamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Tiletamine.
TimololMethohexital may increase the hypotensive activities of Timolol.
TizanidineMethohexital may increase the hypotensive activities of Tizanidine.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methohexital.
TolcaponeThe risk or severity of adverse effects can be increased when Methohexital is combined with Tolcapone.
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be increased when combined with Methohexital.
TopiramateThe risk or severity of adverse effects can be increased when Methohexital is combined with Topiramate.
TorasemideMethohexital may increase the hypotensive activities of Torasemide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methohexital.
TrandolaprilMethohexital may increase the hypotensive activities of Trandolapril.
TranilastThe metabolism of Tranilast can be increased when combined with Methohexital.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Methohexital is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Methohexital is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Trazodone.
TriamtereneMethohexital may increase the hypotensive activities of Triamterene.
TriazolamThe risk or severity of adverse effects can be increased when Methohexital is combined with Triazolam.
TrichlormethiazideMethohexital may increase the orthostatic hypotensive activities of Trichlormethiazide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Trifluoperazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Triflupromazine.
TrimipramineThe risk or severity of adverse effects can be increased when Methohexital is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Triprolidine.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Methohexital.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methohexital.
ValsartanMethohexital may increase the hypotensive activities of Valsartan.
VerapamilMethohexital may increase the hypotensive activities of Verapamil.
VigabatrinThe risk or severity of adverse effects can be increased when Methohexital is combined with Vigabatrin.
VilazodoneThe risk or severity of adverse effects can be increased when Methohexital is combined with Vilazodone.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Methohexital.
VortioxetineThe risk or severity of adverse effects can be increased when Methohexital is combined with Vortioxetine.
WarfarinThe metabolism of Warfarin can be increased when combined with Methohexital.
XylazineThe risk or severity of adverse effects can be increased when Methohexital is combined with Xylazine.
XylometazolineThe metabolism of Xylometazoline can be increased when combined with Methohexital.
ZaleplonThe risk or severity of adverse effects can be increased when Methohexital is combined with Zaleplon.
ZiconotideThe metabolism of Ziconotide can be increased when combined with Methohexital.
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Methohexital.
ZimelidineThe risk or severity of adverse effects can be increased when Methohexital is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methohexital.
ZolazepamThe risk or severity of adverse effects can be increased when Methohexital is combined with Zolazepam.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methohexital.
ZonisamideThe risk or severity of adverse effects can be increased when Methohexital is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Methohexital is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Methohexital is combined with Zotepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Methohexital is combined with Zuclopenthixol.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Inhibitory extracellular ligand-gated ion channel activity
Specific Function:
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine. Functions as receptor for diazepines and various anesthetics, such as pentobarbital; these are bound at a separate allosteric effector binding site. Functions as ligand-gated chloride channel (By si...
Gene Name:
GABRA1
Uniprot ID:
P14867
Molecular Weight:
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Koltchine VV, Ye Q, Finn SE, Harrison NL: Chimeric GABAA/glycine receptors: expression and barbiturate pharmacology. Neuropharmacology. 1996;35(9-10):1445-56. [PubMed:9014160 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23